111 related articles for article (PubMed ID: 29187468)
1. Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.
Ducoulombier S; Golfier F; Colomban O; Benayoun D; Bolze PA; Tod M; You B
Anticancer Res; 2017 Dec; 37(12):6879-6886. PubMed ID: 29187468
[TBL] [Abstract][Full Text] [Related]
2. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
3. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
Li C; Cui Q; Wang X; Yao S; Tu H; Chen M
BMC Cancer; 2024 May; 24(1):609. PubMed ID: 38769484
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
Bouvarel B; Colomban O; Frenel JS; Loaec C; Bourgin C; Berton D; Freyer G; You B; Classe JM
Int J Gynecol Cancer; 2024 Apr; 34(4):574-580. PubMed ID: 38242546
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
Lee YJ; Lee IH; Kim YJ; Chung YS; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
PLoS One; 2018; 13(9):e0203366. PubMed ID: 30188915
[TBL] [Abstract][Full Text] [Related]
6. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
[TBL] [Abstract][Full Text] [Related]
7. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
[TBL] [Abstract][Full Text] [Related]
8. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
You B; Colomban O; Heywood M; Lee C; Davy M; Reed N; Pignata S; Varsellona N; Emons G; Rehman K; Steffensen KD; Reinthaller A; Pujade-Lauraine E; Oza A
Gynecol Oncol; 2013 Aug; 130(2):289-94. PubMed ID: 23694718
[TBL] [Abstract][Full Text] [Related]
9. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
10. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
11. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
You B; Robelin P; Tod M; Louvet C; Lotz JP; Abadie-Lacourtoisie S; Fabbro M; Desauw C; Bonichon-Lamichhane N; Kurtz JE; Follana P; Leheurteur M; Piano FD; Ferron G; De Rauglaudre G; Ray-Coquard I; Combe P; Chevalier-Place A; Joly F; Leary A; Pujade-Lauraine E; Freyer G; Colomban O
Clin Cancer Res; 2020 Sep; 26(17):4625-4632. PubMed ID: 32209570
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer.
Deo SV; Goyal H; Shukla NK; Raina V; Kumar L; Srinivas G
Indian J Cancer; 2006; 43(3):117-21. PubMed ID: 17065769
[TBL] [Abstract][Full Text] [Related]
13. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
Gasowska-Bodnar A; Bodnar L; Wcisło GB; Jerzak MM; Szczylik C; Baranowski W
Ginekol Pol; 2008 Feb; 79(2):108-14. PubMed ID: 18510089
[TBL] [Abstract][Full Text] [Related]
14. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
Obeidat B; Latimer J; Crawford R
Gynecol Obstet Invest; 2004; 57(3):153-6. PubMed ID: 14726621
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
[TBL] [Abstract][Full Text] [Related]
16. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
Chi DS; Venkatraman ES; Masson V; Hoskins WJ
Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
[TBL] [Abstract][Full Text] [Related]
17. A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer.
Risum S; Høgdall E; Engelholm SA; Fung E; Lomas L; Yip C; Petri AL; Nedergaard L; Lundvall L; Høgdall C
Int J Gynecol Cancer; 2009 Dec; 19(9):1535-8. PubMed ID: 19955932
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the survival of patients with advanced-stage ovarian cancer patients undergoing interval cytoreduction with the use of computed tomography reevaluation after neoadjuvant chemotherapy.
Li JY; Wang R
J Obstet Gynaecol Res; 2023 Nov; 49(11):2700-2710. PubMed ID: 37528642
[TBL] [Abstract][Full Text] [Related]
20. Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer.
Ackroyd SA; Thomas S; Angel C; Moore R; Meacham PJ; DuBeshter B
J Robot Surg; 2018 Jun; 12(2):245-250. PubMed ID: 28631233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
